期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

PPARs、TZD与肾脏疾病 被引量：4

下载PDF
导出
摘要 过氧化物酶体增殖物激活受体 (PPARs)是配体激活的转录因子 ,它有三种亚型 ,即PPARα、PPARβ/δ和PPARγ。噻唑烷二酮 (TZD)是PPARγ的特异性配体 ,其与PPARγ结合后 ,能改善胰岛素抵抗 ,影响肾血流动力学、炎症反应 ,减轻蛋白尿及防止肾维化等作用 。
作者 陈利群 甘华
机构地区 重庆医科大学附属第一医院肾内科
出处 《国外医学（泌尿系统分册）》 2004年第4期526-528,共3页 Foreign Medical Sciences(Urology and Nephrology Foreign Medical Sciences)
关键词 肾疾病 受体 细胞表面
分类号 R692 [医药卫生—泌尿科学]
  • 相关文献

参考文献19

  • 1Guan Y,Breyer MD.Peroxisome proliferator-activated receptors(PPARs):Novel therapeutic targets in renal disease.Kidney Int,2001,60,14～30
  • 2Smith SA,Lister CA,Toseland CD,et al.Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in Zucker diabetic fatty rat.Diabetes Obes Metab,2000,2,363～372
  • 3Haraguchi K,Shimura H,Onaya T.Suppression of experimental crescentic glomerulonephritis by peroxisome proliferator-activated receptor(PPAR) gamma activators.Clin Exp Nephrol,2003,7,27～32
  • 4Ma L,Marcantoni C,Linton MF,et al.Peroxisome proliferator-activated receptor-gamma agonist troglitazone protects against non-diabetic glomerulosclerosis in rats.Kidney Int,2001,59,1899～1910
  • 5Fliser D,Pacini G,Engelleiter R,et al.Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease.Kidney Int,1998,53(5),1343～7
  • 6Isshiki K,Haneda M,Koya D,et al.Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetes rats.Diabetes,2000,49,1022～1032
  • 7Winer N,Weber MA,Sowers JR.The effect of antihypertensive drugs on vascular compliance.Curr Hypertens Rep,2001,3,297～304
  • 8Collins AR,Noh G,Hsueh WA,et al.PPARgamma ligands attenuate angiotensin-II accelerated atherosclerosis in male low density lipoprotein receptor deficient(LDLR-/-) mice.Diabetes,2001,50,A149
  • 9Diep QN,El Mabrouk M,Cohn JS,et al.Structure,endothelial function,cell growth,and inflammation in blood vessels of angiotensin II-infused rats:role of peroxisome proliferator-activated receptor-gamma.Circulation,2002,105,2296～2302
  • 10Renault MA,Jalvy S,Belloc I,et al.AP-1 is involved in UTP-induced osteopontin expression in arterial smooth muscle cells.Circ Res,2003

二级参考文献13

  • 1Mangelsdorf DJ, Thummel C, Beato M, et al. The nuclear receptor superfamily: the second decade (overview). Cell, 1995, 83:835-839.
  • 2Murphy GJ, Holder JC. PPARγ agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol Sci, 2000, 21:469-474.
  • 3Guan YF, Breyer MD. Peroxisome proliferator-activated receptors (PPARs): novel therapeutic targets in renal disease. Kidney Int, 2001, 60:14-30.
  • 4McCarthy KJ, Routh RE, Shaw W, et al. Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion. Kidney Int, 2000, 58:2341-2350.
  • 5Ma L, Marcantoni C, Linton MF, et al. Peroxisome proliferator-activated receptor-γ agonist troglitazone protects against non-diabetic glomerulosclerosis in rats. Kidney Int, 2001, 59:1899-1910.
  • 6Haraguchi K, Wakasugi M, Shimura H, et al. Peroxisome proliferator-activated receptor-γ suppresses crescent glomerulonephritis induced by nephrotoxic serum. J Am Soc Nephrol, 2001, 12:652A (A3395).
  • 7Han J, Hajjar DP, Tauras JM, et al. Transforming growth factor-β1 (TGF-β1) and TGF-β2 decrease expression of CD36, the type b scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor-γ. J Biological Chem, 2000, 275:1241-1246.
  • 8Leininger MT, Portocarrero CP, Houseknecht KL. Peroxisome proliferator-activated receptor-γ1 expression in porcine white blood cells: dynamic regulation with acute endotoxemia. Biochem Biophy Res Commu, 1999, 263:749-753.
  • 9Huang JT, Welch JS, Ricote M, et al. Interleukin-4-dependent production of PPARγ ligands in macrophages by 12/15-lipoxygenase. Nature, 1999, 400:378-382.
  • 10Ricote M, Li AC, Willson TM, et al. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature, 1998, 391:79-82.

共引文献18

同被引文献51

  • 1王焕君,黄雯,李曙远.银杏叶提取物对早期糖尿病肾病患者尿内皮素的影响[J].山东中医药大学学报,2004,28(4):282-283. 被引量：5
  • 2张建梅,李秀钧.噻唑烷二酮类的降糖外作用[J].中国医院用药评价与分析,2005,5(1):57-59. 被引量：3
  • 3王炯.TGF－β的生物学效应及其在某些疾病中的作用[J].国外医学（免疫学分册）,1995,18(1):18-21. 被引量：11
  • 4Lea JP, Nicholas SB. Diabetes mellitus and hypertension: key risk factors for kidney disease[J]. J Natl Med Assoc, 2002, 94(8): 7
  • 5Locatelli F, Canand B, EckardtK U, et al. The importance of diabetic nephropathy in currentnephrologicalpractice[J] . Nephrol Dial Transpl, 2003, 18(9): 1716 -172
  • 6Noh HJ, KimHC, Lee SS, et al. The inhibitory effect of siRNAs on the high glucose - induced overexpression of TGF - beta1 inmesangial cells [J]. J Korean Med Sci, 2006, 21 (3): 430 -435
  • 7Meyer H, Szukics B, Neubauer K, et al. Extracellular matrix proteins as early markers in diabetic nephropathy[J] . Eur J Clin Chem Clin Biocbem, 1995,33 (4) : 211
  • 8Bernard Portha. Programmed disorders of β-cell development and function as one cause for type 2 diabetes[J] . Diabetes Metab Res Rev, 2005, 21 (6): 495 - 504
  • 9杨滨.中药糖耐康治疗糖耐量低减临床观察[D]中国优秀硕士学位论文全文数据库.北京中医药大学,2007.
  • 10Kern PA. The expression of TNFα in human adipose tissue regulation by obesity,weight loss and relationship to lipoprotein lipase[J].J Clin Invest, 1995,95:2111.

引证文献4

二级引证文献14

国外医学（泌尿系统分册）
2004年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部